Superior Toxicology Data from Antikor’s FDC Platform

Tours, France, June 27th, 2017: Antikor Biopharma Limited (Antikor), a leader in advancing antibody fragment-drug conjugates (FDCs), will be presenting new data at the 5th Antibody Industrial Symposium in Tours, France. Dr Yahioglu, Director of Chemistry and co-founder will give an overview of Antikor's unique small-format platform technology that combines the rapid and effective penetration of solid tumours with the faster clearance from normal organs. New data will show that using a highly potent, clinically-validated cytotoxic payload, FDCs are better tolerated and less toxic than antibody-drug conjugates (ADCs) carrying the same quantity of payload.

Dr Yahioglu commented, "These pivotal data strengthen Antikor's proposition that highly-loaded FDCs can be a superior approach to treating solid tumours, whilst further reducing the risk of liver, renal and haematological toxicities often associated with whole ADCs." Dr Deonarain, Antikor's CEO and CSO commented, "The major issue about applying ADCs successfully in oncology is getting a wide enough therapeutic window in patients. Our data suggest that our approach can open up this window whilst hitting solid tumours more effectively".

For more information about this conference, see http://ais2017.fr/

For more information please contact:
Dr Carlos Pittol, Business Development Director,
carlos.pittol@antikor.co.uk

About Antikor

Antikor Biopharma Ltd is a private multidisciplinary biopharmaceutical company spun out from Imperial College London. The company is located at the Stevenage Bioscience Catalyst on the GSK site close to the life science clusters of Cambridge and London. The company is leveraging technologies acquired from Photobiotics (now a subsidiary company) in the development of more effective Antibody-Drug Conjugates in the treatment of numerous cancers and in other therapeutic areas.

About Antibody-Drug Conjugates

Antibody Drug Conjugates (ADCs) are a relatively new type of therapeutic comprising a targeting molecule (an antibody) linked to a cytotoxic drug. When a patient is treated with an ADC, the antibody specifically directs the drug to the tumour cell and kills it. Traditional chemotherapeutic agents cannot be specifically targeted in this way. ADC targeted therapy is one of the most rapidly expanding areas in the biotech sector, with numerous significant partnership deals in place. Two current next generation ADCs, Kadcyla and Adcetris, have been approved recently in breast cancer and lymphoma, respectively, and other drug candidates are in the development pipeline. Major pharmaceutical companies are taking a real interest in this field, leading to licensing opportunities for biotechnology companies specialising in antibody-drug conjugation technologies.